Search Results for: Alize Pharma II Acquired by
Articles
Alize Pharma II Acquired by Jazz Pharmaceuticals May 17, 2016
Alizé Pharma II recently announced that a subsidiary of Jazz Pharmaceuticals plc has acquired 100% of its shares. This all-cash...Noramco Announces Strategic Alignment With Purisys & Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API & Drug Product Supply Chain Services Provider March 14, 2024
Noramco recently announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired….
Zenas BioPharma Announces Strategic License & Collaboration Agreement With Bristol Myers Squibb September 5, 2023
Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases….
Sermonix Pharmaceuticals & Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial February 13, 2023
Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative recently announced Sermonix’s investigational next-generation targeted endocrine therapy, lasofoxifene, will be evaluated...Lantern Pharma & Allarity Therapeutics Enter Into Agreement for Future Clinical Development of Irofulven July 28, 2021
Allarity Therapeutics A/S and Lantern Pharma Inc. recently announced they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Specialized Capabilities for Small & Large Molecules June 4, 2020
Contributor Cindy H. Dubin interviews key players in the CDMO market who present case studies about how they are helping pharmaceutical and biopharma companies overcome a variety of formulation and manufacturing challenges.
PERSONALIZED MEDICINE - Personalizing Cancer Immunotherapy: Trends in Biomarker Discovery January 14, 2020
Emile Youssef, MD, PhD, says due to tumor heterogeneity, the plasticity and diversity of cancer cells, and a multitude of other factors, biomarker development is a challenge, and thus explores four trends in cancer biomarker discovery.
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals December 4, 2019
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
Paragon Bioservices to be Acquired for $1.2 Billion April 15, 2019
Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
Debiopharm Acquires Phase II Asset From ImmunoGen May 30, 2017
Debiopharm International SA, part of Debiopharm Group, recently announced that it has acquired ImmunoGen’s IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC...Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase III Study April 24, 2017
Motif Bio plc recently announced positive topline results from REVIVE-1, a global Phase III clinical trial of its investigational drug...TiGenix Receives Positive Feedback From the FDA on Global Phase III Trial Protocol March 17, 2017
TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem...MGB Biopharma Successfully Completes Phase I Clinical Trial December 15, 2015
MGB Biopharma recently announced it has successfully completed a Phase I clinical trial of an oral formulation of its lead...SINGLE-USE MARKET - Rise of Single-Use Technologies & Systems in Biopharmaceuticals November 19, 2015
Kevin James and Shalini S. Dewan of BCC Research believe eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently, this requires high-level monitoring of critical manufacturing processes. Single-use technology aids biopharmaceutical manufacturers in overcoming this challenge by reducing or eliminating the need for sterilization between batches, thereby improving operational efficiency.
Innate Pharma and AstraZeneca Announce Global Agreement May 5, 2015
Innate Pharma SA recently announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its...Astellas Pharma & Drais Pharmaceuticals to Launch Virtual Co. May 14, 2013
Astellas Pharma Inc. and Drais Pharmaceuticals, Inc.recently announced they have entered into a third partnership in the past year to...Royalty Pharma Buys an Interest in Fumaderm for $761 Million May 6, 2012
Royalty Pharma recently announced it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG...Inhibitex to be Acquired by Bristol-Myers Squibb for $2.5 Billion January 12, 2012
Bristol-Myers Squibb Company and Inhibitex, Inc. recently announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will...Activartis Develops Cancer Vaccine in Phase II, Seeks Partner October 27, 2011
Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that is currently in Phase...ICIG to Acquire Pharmaceutical Intermediates Business From Genzyme February 27, 2011
International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG...
